Ania Dabrowski1, Thomas J Robinson1, Ryan J Felling2. 1. Department of Neurology, Johns Hopkins School of Medicine, 200 N. Wolfe Street, Suite 2158, Baltimore, MD, 21287, USA. 2. Department of Neurology, Johns Hopkins School of Medicine, 200 N. Wolfe Street, Suite 2158, Baltimore, MD, 21287, USA. rfelling@jhmi.edu.
Abstract
PURPOSE OF REVIEW: After decades of hype, cell-based therapies are emerging into the clinical arena for the purposes of promoting recovery after stroke. In this review, we discuss the most recent science behind the role of cell-based therapies in ischemic stroke and the efforts to translate these therapies into human clinical trials. RECENT FINDINGS: Preclinical data support numerous beneficial effects of cell-based therapies in both small and large animal models of ischemic stroke. These benefits are driven by multifaceted mechanisms promoting brain repair through immunomodulation, trophic support, circuit reorganization, and cell replacement. Cell-based therapies offer tremendous potential for improving outcomes after stroke through multimodal support of brain repair. Based on recent clinical trials, cell-based therapies appear both feasible and safe in all phases of stroke. Ongoing translational research and clinical trials will further refine these therapies and have the potential to transform the approach to stroke recovery and rehabilitation.
PURPOSE OF REVIEW: After decades of hype, cell-based therapies are emerging into the clinical arena for the purposes of promoting recovery after stroke. In this review, we discuss the most recent science behind the role of cell-based therapies in ischemic stroke and the efforts to translate these therapies into human clinical trials. RECENT FINDINGS: Preclinical data support numerous beneficial effects of cell-based therapies in both small and large animal models of ischemic stroke. These benefits are driven by multifaceted mechanisms promoting brain repair through immunomodulation, trophic support, circuit reorganization, and cell replacement. Cell-based therapies offer tremendous potential for improving outcomes after stroke through multimodal support of brain repair. Based on recent clinical trials, cell-based therapies appear both feasible and safe in all phases of stroke. Ongoing translational research and clinical trials will further refine these therapies and have the potential to transform the approach to stroke recovery and rehabilitation.
Authors: Claudia Bühnemann; Andreas Scholz; Christian Bernreuther; Christoph Y Malik; Holger Braun; Melitta Schachner; Klaus G Reymann; Marcel Dihné Journal: Brain Date: 2006-10-03 Impact factor: 13.501
Authors: Douglas J Cook; Cynthia Nguyen; Hyun N Chun; Irene L Llorente; Abraham S Chiu; Michal Machnicki; Thomas I Zarembinski; S Thomas Carmichael Journal: J Cereb Blood Flow Metab Date: 2016-07-20 Impact factor: 6.200
Authors: Pouria Moshayedi; Lina R Nih; Irene L Llorente; Andrew R Berg; Jessica Cinkornpumin; William E Lowry; Tatiana Segura; S Thomas Carmichael Journal: Biomaterials Date: 2016-08-02 Impact factor: 12.479
Authors: Phillip Larimer; Julien Spatazza; Juan Sebastian Espinosa; Yunshuo Tang; Megumi Kaneko; Andrea R Hasenstaub; Michael P Stryker; Arturo Alvarez-Buylla Journal: Cell Rep Date: 2016-07-14 Impact factor: 9.423
Authors: Muhammad E Haque; Khader M Hasan; Sarah George; Clark Sitton; Seth Boren; Octavio D Arevalo; Farhaan Vahidy; Xu Zhang; Charles S Cox; Susan Alderman; Jaroslaw Aronowski; James C Grotta; Sean I Savitz Journal: Stem Cells Transl Med Date: 2021-03-10 Impact factor: 6.940